This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.

Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.

Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.

Novo Nordisk A/S reports that in the Frontier 2 study, their once-weekly and once-monthly Mim8 treatments significantly outperformed standard and prior prophylaxis treatments in reducing bleeding episodes in individuals with haemophilia A.

Mabwell reported progress in its clinical trial of the novel Nectin-4 targeting ADC (9MW2821) for triple-negative breast cancer treatment.

AC Immune and Takeda Enter an Exclusive Deal for Licence and Option on Active Immunotherapy Focused on Amyloid Beta for Alzheimer's Disease.

Kodiak Sciences has started treating initial participants in the Phase 3 GLOW2 study, examining Tarcocimab Tedromer for diabetic retinopathy.

Ajax Therapeutics has received FDA approval for its investigational new drug application for AJ1-11095, a novel Type II JAK2 inhibitor, intended for the management of myelofibrosis.

FDA grants priority review to Dupixent® (dupilumab) sBLA for treating teens with chronic rhinosinusitis and nasal polyps.

Cardurion Pharmaceuticals Reports Encouraging Outcomes from Phase 2a CARDINAL-HF Study of PDE9 Inhibitor in Heart Failure Patients.

Anaptys released encouraging initial outcomes from the GEMINI-2 Phase 3 study of Imsidolimab (IL-36R) for treating Generalized Pustular Psoriasis.

Fusion Pharmaceuticals revealed that the initial participant has received a dose in the AlphaBreak Trial's Phase 2 study of FPI-2265 for treating metastatic castration-resistant prostate cancer.